Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placebo-Controlled Clinical Trials
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Evidence supporting the use of second generation antipsychotics (SGAs) in the treatment of acute depression with mixed features (MFs) associated with bipolar disorder (BD) is scarce and equivocal. Therefore, we conducted a systematic review and preliminary meta-analysis investigating SGAs in the treatment of acute BD depression with MFs. Two authors independently searched major electronic databases from 1990 until September 2015 for randomized (placebo-) controlled trials (RCTs) or open-label clinical trials investigating the efficacy of SGAs in the treatment of acute bipolar depression with MFs. A random-effect meta-analysis calculating the standardized mean difference (SMD) between SGA and placebo for the mean baseline to endpoint change in depression as well as manic symptoms score was computed based on 95% confidence intervals (CI). Six RCTs and one open-label placebo-controlled studies (including post-hoc reports) representing 1023 patients were included. Participants received either ziprasidone, olanzapine, lurasidone, quetiapine or asenapine for an average of 6.5 weeks across the included studies. Meta-analysis with Duval and Tweedie adjustment for publication bias demonstrated that SGA resulted in significant improvements of (hypo-)manic symptoms of bipolar mixed depression as assessed by the means of the total scores of the Young Mania Rating Scale (YMRS) (SMD −0.74, 95% CI −1.20 to −0.28, n SGA = 907, control = 652). Meta-analysis demonstrated that participants in receipt of SGA (n = 979) experienced a large improvement in the Montgomery–Åsberg Depression Rating Scale (MADRS) scores (SMD −1.08, 95% CI −1.35 to −0.81, p < 0.001) vs. placebo (n = 678). Publication and measurement biases and relative paucity of studies. Overall, SGAs appear to offer favorable improvements in MADRS and YMRS scores vs. placebo. Nevertheless, given the preliminary nature of the present report, additional original studies are required to allow more reliable and clinically definitive conclusions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Forest plot of the Young Mania Rating Scale (YMRS) across the included studies. CI = confidence intervals. Referenced studies: McIntyre R.S. et al., 2015 [29]; Patkar A. et al., 2012 [33] & Pae C.U. et al., 2012 [34].](https://figures.cochat.ai/paper-figures/061757f57b3b4f7bbd184144ae09b4bb/atypical-antipsychotics-in-the-treatment-of-acute-bipolar-depression-with-mixed-figure-2.jpg)
![Figure 3 Forest plot of the Montgomery–Åsberg Depression Rating Scale (MADRS) across the included studies. Referenced studies: Tohen M. et al., 2014 [14]; Patkar A. et al., 2012 [33] & Pae C.U. et al., 2012 [34]; Berk M. et al., 2015 [31]; McIntyre R.S. et al., 2015 [29].](https://figures.cochat.ai/paper-figures/bbe7fc371ecc4b39bded29f44b0f34ce/atypical-antipsychotics-in-the-treatment-of-acute-bipolar-depression-with-mixed-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pooled analysis indicates that atypical antipsychotics show a class effect in alleviating mixed features in bipolar depression, with olanzapine‐fluoxetine combination, asenapine, and lurasidone all demonstrating efficacy.319”
From Canadian Network for Mood and Anxiety Treatments ( CANMAT ) and International Society for Bipolar Disorders ( ISBD ) 2018 guidelines for the management of patients with bipolar disorder (2018) · cites this paper as [319]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 8×
“Approximation of the HAM-D17 scores to the corresponding MADRS approximated values was planned when needed using conventional guidance [58].”
MethodInfluentialDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
(2014) · Medical Entomology and Zoology · Cited by 17,633
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 5×
“It was possible to pool dat from three studies [14,29,33] investigating the YMRS [38] including 907 alloc ted to SGA and 652 allocated in to the control arm.”
MethodInfluentialAssessing the Quality of Randomized Trials
Clark, H. D., Wells, G. A., Huët, C., McAlister, F. A., Salmi, L. R., Fergusson, D., & Laupacis, A. (1999) · Controlled Clinical Trials · doi:10.1016/s0197-2456(99)00026-4 · Cited by 648
Davey, J., Turner, R. M., Clarke, M. J., & Higgins, J. P. (2011) · BMC Medical Research Methodology · doi:10.1186/1471-2288-11-160 · Cited by 404 · cited 1×
“Indeed, as little as two studies should be acceptable for a preliminary meta-analytic report, even when accounting for heterogeneous active compounds in the same class of drugs and/or differential doses [52], whereas those meta-analysis accounting for substantially heterogeneous compounds and/or based on incomplete so…”
Background
Research works printed but not linked: 1
- Prieto M.L. Ozerdem A. Quiroz D. Altinbas K. Aydemir O. Yalin N. Feeder S.E. Geske J.R. Frye M.A. Exploratory factor analysis of mixed depression utilizing a modified version of Hypomania Checklist 32 (mHCL-32) Bipolar Disord. 2013 15 114
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Luchini, C., Stubbs, B., Solmi, M., & Veronese, N. (2017) · World Journal of Meta-Analysis · doi:10.13105/wjma.v5.i4.80 · Cited by 977
Self-citationMcIntyre, R. S., Suppes, T., Earley, W., Patel, M., & Stahl, S. M. (2020) · CNS Spectrums · doi:10.1017/s1092852919001287 · Cited by 201
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187
“For this reason, the task force also feels that the inclusion of this post hoc analysis in the metaanalysis by Fornaro et al. (2016) entitled ‘Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: a systematic review and exploratory meta-analysis of…”
BackgroundDo Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview
Pompili, M., Baldessarini, R., Forte, A., Erbuto, D., Serafini, G., Fiorillo, A., Amore, M., & Girardi, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101700 · Cited by 78
Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment
Tondo, L., & Baldessarini, R. J. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0715-0 · Cited by 71
Müller, H., Moeller, S., Lücke, C., Lam, A. P., Braun, N., & Philipsen, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00239 · Cited by 81
Morbidity in depressive disorders
Baldessarini, R. J., Forte, A., Selle, V., Sim, K., Tondo, L., Undurraga, J., & Vázquez, G. H. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000448661 · Cited by 63
Mixed States in Bipolar Disorder: Etiology, Pathogenesis and Treatment
Muneer, A. (2017) · Chonnam Medical Journal · doi:10.4068/cmj.2017.53.1.1 · Cited by 70
Prevention of suicidal behavior with lithium treatment in patients with recurrent mood disorders
Tondo, L., & Baldessarini, R. J. (2024) · International Journal of Bipolar Disorders · doi:10.1186/s40345-024-00326-x · Cited by 50
Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews
Fornaro, M., Berardis, D. D., Perna, G., Solmi, M., Veronese, N., Orsolini, L., Buonaguro, E. F., Iasevoli, F., Köhler, C. A., Carvalho, A. F., et al. (2017) · BioMed Research International · doi:10.1155/2017/3084859 · Cited by 46
Self-citationFornaro, M., Solmi, M., Veronese, N., Berardis, D. D., Buonaguro, E. F., Tomasetti, C., Perna, G., Preti, A., & Carta, M. G. (2017) · International Review of Psychiatry · doi:10.1080/09540261.2017.1299695 · Cited by 37
Self-citationTavares, D. F., Suen, P. J. C., dos Santos, C. G. R., Moreno, D. H., Valiengo, L. D. C. L., Klein, I., Borrione, L., Forte, P. M., Brunoni, A. R., & Moreno, R. A. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01080-9 · Cited by 29
Malhi, G. S., Byrow, Y., Outhred, T., & Fritz, K. (2016) · CNS Spectrums · doi:10.1017/s1092852916000614 · Cited by 29
Fornaro, M., Anastasia, A., Monaco, F., Novello, S., Fusco, A., Iasevoli, F., Berardis, D. D., Veronese, N., Solmi, M., & de Bartolomeis, A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.085 · Cited by 28
Self-citationEarley, W. R., Burgess, M. V., Rekeda, L., Hankinson, A. L., McIntyre, R. S., Suppes, T. M., Calabrese, J. R., & Yatham, L. N. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.098 · Cited by 30
Lin, S., Yang, S., Park, S., Jang, O., Zhu, X., Xiang, Y., Ouyang, W., Javed, A., Khan, M. N. S., Grover, S., et al. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.1.61 · Cited by 25
Murray, R. M., Correll, C. U., Reynolds, G. P., & Taylor, D. M. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317693200 · Cited by 27
D’Urso, G., Toscano, E., Barone, A., Palermo, M., Dell’Osso, B. M., Lorenzo, G. D., Mantovani, A., Martinotti, G., Fornaro, M., Iasevoli, F., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110672 · Cited by 29
Self-citationCariprazine for the treatment of bipolar depression: a review
Ragguett, R., & McIntyre, R. S. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1580571 · Cited by 26
Durgam, S., Kozauer, S. G., Earley, W. R., Chen, C., Huo, J., Lakkis, H. D., Stahl, S. M., & McIntyre, R. S. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001964 · Cited by 23
Screening mixed depression and bipolarity in the postpartum period at a primary health care center
Çelik, S. B., Bucaktepe, G. E., Uludağ, A., Bulut, İ. U., Erdem, Ö., & Altınbaş, K. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.07.013 · Cited by 20
Mixed states in bipolar disorder – changes in DSM-5 and current treatment recommendations
Betzler, F., Stöver, L., Sterzer, P., & Köhler, S. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1311921 · Cited by 25
Adverse effects associated with antipsychotic use in older adults
Khalid, J., & Aparasu, R. R. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2386377 · Cited by 17
“It is important to acknowledge that AP use in conditions like affective disorders or acute depression with mixed features in bipolar disorder or treatment-resistant anxiety may lead to distinct adverse effects, which should be considered in the context of the specific disorder treated [11,12].”
Treatment of Mixed Features in Bipolar Disorder: an Updated View
Chakrabarty, T., Keramatian, K., & Yatham, L. N. (2020) · Current Psychiatry Reports · doi:10.1007/s11920-020-1137-6 · Cited by 20
Advances in the psychopharmacotherapy of bipolar disorder type I
Sleem, A., & El‐Mallakh, R. S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1893306 · Cited by 16
Lin, Y., Chen, Y. B., Hung, K., Liang, C., Tseng, P., Carvalho, A. F., Vieta, E., Solmi, M., Lai, E. C., Lin, P., et al. (2024) · BMJ Mental Health · doi:10.1136/bmjment-2024-301165 · Cited by 20
Self-citationKucia, K. A., Merk, W., Zapałowicz, K., & Mędrala, T. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s217816 · Cited by 16
Faedda, G. L., & Marangoni, C. (2016) · CNS Spectrums · doi:10.1017/s1092852916000493 · Cited by 15
Fornaro, M., Kardash, L., Novello, S., Fusco, A., Anastasia, A., Berardis, D. D., Perna, G., & Carta, M. G. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1428554 · Cited by 16
Self-citationRopinirole Augmentation for Depression: A Randomized Controlled Trial Pilot Study
Gershon, A. A., Amiaz, R., David, H. S., & Grunhaus, L. J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000984 · Cited by 11
Wang, Z., Zhang, D., Du, Y., Wang, Y., Huang, T., Ng, C. H., Huang, H., Pan, Y., Lai, J., & Hu, S. (2023) · Pharmaceuticals · doi:10.3390/ph16020287 · Cited by 11
Sepede, G., Lorusso, M., Spano, M. C., Nanno, P. D., Iorio, G. D., & Giannantonio, M. D. (2018) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000297 · Cited by 11
Chang, H.-Y., Tseng, P., Stubbs, B., Chu, C., Li, D., Fornaro, M., Carvalho, A. F., Solmi, M., Veronese, N., Vieta, E., et al. (2017) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000148 · Cited by 11
Self-citationMonreal, J. A., Duval, F., Mokrani, M., Fattah, S., & Palao, D. J. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.02.009 · Cited by 8
Treatment of Acute and Maintenance Phase of Bipolar Depression
Erten, E. (2021) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.27408 · Cited by 9
Clinical practice guidelines for the management of bipolar disorder: 2025 update
Menon, V., Ganesh, R., Deep, R., Sarkhel, S., Goswami, S., Mohapatra, D., Munoli, R. N., Sharma, P., Reddy, M., & Muralidharan, K. (2026) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry_1186_25 · Cited by 10
Bipolar disorder: The foundational role of mood stabilizers
Shah, B. (2023) · Current Psychiatry · doi:10.12788/cp.0346 · Cited by 5
Acne caused by ziprasidone in a young patient with bipolar disorder: A case report
Yuan, Y., Li, X., Jiang, X., Li, Z., Ou, Y., & Li, Z. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.948977 · Cited by 3
Antipsychotiques : quand et comment les prescrire ?
Tebeka, S., Airagnes, G., & Limosin, F. (2017) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2016.12.007 · Cited by 9
Atypical Antipsychotics in Major Depressive Disorder
Orsolini, L., Vellante, F., Valchera, A., Fornaro, M., Carano, A., Pompili, M., Perna, G., Serafini, G., Nicola, M. D., Martinotti, G., et al. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_18 · Cited by 3
Self-citationGao, S., Chen, Y., Liu, J., Zhang, Q., Zhao, X., Liu, B., Zhang, Y., Li, L., & Wang, G. (2025) · Psychological Medicine · doi:10.1017/s0033291725101955 · Cited by 2
Quetiapine combined with escitalopram in the treatment of bipolar depression
Zhang, P., Huang, J., Xiong, Z., Liu, X., & Haiying, P. (2025) · The International Journal of Psychiatry in Medicine · doi:10.1177/00912174251316653 · Cited by 1
Haralanov, S., Haralanova, E., Bogdanova, D., Dimitrov, R., Milushev, E., & Shkodrova, D. (2021) · Springer eBooks · doi:10.1007/978-3-030-61721-9_39 · Cited by 2
Essential Pharmacotherapies for Bipolar Disorder
Ruegg, H., Adler, C. M., Durán, L. R. P., Watson, S., & DelBello, M. P. (2019) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-018-0162-0 · Cited by 1
Suicide in psychiatric disorders: rates, risk factors, and therapeutics
Tondo, L., & Baldessarini, R. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00004-6 · Cited by 1
Tavares, D. F. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2021.tde-20102021-142753 · Cited by 3
Berardis, D. D., Fornaro, M., Orsolini, L., Vellante, F., Carano, A., Valchera, A., Tomasetti, C., Martinotti, G., & Di Giannantonio, M. (2018) · Bipolar Disorder Open Access · doi:10.4172/2472-1077.1000123
Self-citationMaruta, N. (2019) · Ukrains kyi Visnyk Psykhonevrolohii · doi:10.36927/2079-0325-v27-is4-2019-18
Treatment of depressive episodes with mixed features: A systematic review and meta-analysis
Villalón, F., Philippi, R., & Mendoza, F. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.12.011 · Cited by 1
Bipolar disorder in an evolutionary framework: rethinking adaptation, vulnerability, and stigma
Tusconi, M., Dursun, S. M., Cossu, G., & Carta, M. G. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1764726
Psychotherapy for bipolar disorder from historical foundations to integrative personalized care
Ibrahim, N., Mansour, C., & Naja, W. (2026) · Discover Psychology · doi:10.1007/s44202-026-00774-9
Fornaro, M., Lorenzo, C. D., Núñez, N. A., Singh, B., Veldić, M., Sambataro, F., McIntyre, R. S., Frye, M. A., & Miola, A. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122568
Self-citation
Metadata
- Authors
- Fornaro, M., Stubbs, B., De Berardis, D., Perna, G., Valchera, A., Veronese, N., Solmi, M., & Ganança, L.
- Affiliations
- Columbia University (US)
- King's College London (GB)
- National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital. Mazzini, ASL 4, Teramo 64100, Italy
- Hermanas Hospitalarias del Sagrado Corazón de Jesús (IT)
- University of Padua (IT)
- University of Lisbon (PT)
- Corresponding author
- Fornaro, Michele
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2016-02-16
- Volume
- 17
- Issue
- 2
- Pages
- 241
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC4783972
- OpenAlex
- W2284122467
- Cited by
- 53
- References
- 60
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 5 · 2020: 2 · 2019: 7 · 2018: 7 · 2017: 11 · 2016: 5
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Research Portal (King's College London) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by)
- Columbia Academic Commons (Columbia University)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- atypical antipsychotics, bipolar depression, mixed features, bipolar disorder, acute depression, manic symptoms, depressive symptoms, ziprasidone, olanzapine, lurasidone, quetiapine, asenapine, Young Mania Rating Scale, Montgomery-Asberg Depression Rating Scale
- MeSH terms
- Bipolar Disorder, Depression, Humans, Antipsychotic Agents, Treatment Outcome, Controlled Clinical Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.